IL17A, although not changing overall GvHD and graft versus tumor (GVT) activity, contributes to the early development of CD4‐mediated GvHD by promoting the production of proinflammatory cytokines [30] and might have contributed to the bodyweight loss in the early phase after aGvHD induction. The gene discussed is IL17A; the disease is neoplasm.